Mesenchymal Stem Cells in Acute Myocardial Infarction, Feasible

A study by the Department of Cardiology, Leiden University Medical Center, Netherlands, evaluated the feasibility and long-term (up to 5 years) safety of intramyocardial injection of bone marrow-derived, mesenchymal stem cells (MSC) shortly after acute MI. The main finding from the current study is that MSC treatment, a type of regenerative therapy, is feasible and safe at short term and up to 5 years of follow-up.

Bone marrow-derived MSCs are a promising cell type for cell-based therapy. In preclinical studies, MSC transplantation resulted in improved Left Ventricular function, increased capillary density and reduced infarct size in models of acute MI.

 

Global Left Ventricular (LV) function assessed by echocardiography showed continuous improvements in LV systolic function after MSC injection during the first 12 months that were maintained up to 5 years post-MI.

 

These beneficial effects are most likely related to stimulation of angiogenesis by differentiation of MSCs into endothelial and smooth muscle cells and by paracrine mechanisms, including secretion of a variety of growth factors and cytokines that contribute to cardiac repair. Interestingly, MSCs also have the ability to home to sites of acute tissue injury, the potential to actively suppress the immune system and reduce inflammation and thereby possibly inducing repair and contributing to functional improvement after acute MI.

 

Rehealth has been offering stem cell therapy to treat heart problems for several years now. We use a safe approach that enables you to return to your normal activities within 2 days since we perform those procedures by means of minimally invasive techniques.

 

If you suffer from a cardiac condition and want to be assessed by our team send us your medical reports and we will evaluate your case.